Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Deutsche Bank analyst Pito Chickering upgraded the rating on Boston Scientific (BSX – Research Report) to a Buy today, setting a price target ...

Deutsche Bank upgraded Boston Scientific (BSX) to Buy from Hold with a price target of $108, up from $87. Boston Scientific’s :story has become ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...